 Home > Active Ingredient News > Antitumor Therapy > J Immunother Cancer: Bempegaldesleukin combined with nivolumab in first-line treatment of advanced renal cell carcinoma

J Immunother Cancer: Bempegaldesleukin combined with nivolumab in first-line treatment of advanced renal cell carcinoma

 Last Update: 2022-05-20
 Source: Internet
 Author: User

Tags

cell mediated response

gluten free meaning

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Immunotherapy, particularly immune checkpoint inhibitors (ICIs), has dramatically changed the treatment landscape for patients with advanced renal cell carcinoma (RCC)

The aim of this study was to evaluate the efficacy and safety of the immunostimulatory interleukin-2 cytokine prodrug Bempegaldesleukin (BEMPEG) in combination with nivolumab (NIVO) as first-line therapy in patients with advanced clear cell renal cell carcinoma

This is an open-label, multicohort, multicenter, single-arm, phase 1/2 study; this paper reports results from a phase 1/2 first-line RCC cohort (n=49)

The primary endpoints were objective response rate (ORR) and safety

The objective response rate was 34.

In patients with advanced clear cell renal cell carcinoma , BEMPEG combined with nivolumab as first-line therapy showed preliminary antitumor activity and was well tolerated Treatment regimen showed preliminary antitumor activity and was well tolerated

Original source:

Tannir Nizar M, Cho Daniel C, Diab Adi et al.

Tannir Nizar M, Cho Daniel C, Diab Adi et al.
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study.
[J] .
J Immunother Cancer, 2022, 10: https://doi.
org/10.
1136/jitc-2021-004419.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Erlotinib hydrochloride

CAS No.: 183319-69-9

Industrial Grade or Medical grade

$1/MT EXW

6-Thioguanine

CAS No.: 154-42-7

Industrial Grade or Medical grade

$1/MT EXW

Vinblastine sulfate

CAS No.: 143-67-9

Industrial Grade or Medical grade

$1/MT EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.